What West Pharmaceutical Services's Quarter ended Sep 30, 2026 10-Q says: 4 signals
West Pharmaceutical Services filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses cybersecurity incident, divestiture and margin pressure.
Public (WST)Plastics Manufacturing10,000+ employeeswestpharma.comLinkedIn
Get West Pharmaceutical Services' live signals in Claude or ChatGPT, or by API
What changed at West Pharmaceutical Services this week? Use Autobound signals for westpharma.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 8
Source: Autobound Signal API · 51 signals tracked for West Pharmaceutical Services · updated
10-Q · latest 8
What West Pharmaceutical Services's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
West Pharmaceutical sold SmartDose 3.5mL delivery system and facilities to AbbVie on July 1, 2026
The company completed the sale of its SmartDose 3.5mL On-Body Delivery System assets and associated facilities to AbbVie on July 1, 2026, recording a pre-tax net gain of $55.7 million.
$55.7M
net gain on the sale of SmartDose 3.5mL On-Body Delivery System assets
May 2026 Material Cyberattack Encrypted Systems, Exfiltrated Data, and Incurred SG&A Expenses
In May 2026, West Pharmaceutical Services experienced a cybersecurity incident involving data exfiltration, system encryption, and global operational disruption, incurring $9.2 million in SG&A expenses during the first nine months of 2026.
encryption
The company recorded pre-tax charges of $6.3 million for the quarter and $9.3 million year-to-date related to severance, accelerated depreciation, and legal structure optimization.
$6.3M
pre-tax restructuring charges for the three months ended September 30, 2026
West Vantage gross profit margin declines 2.8 percentage points to 16.5%
West Vantage gross profit dropped 20.8% to $24.0 million with gross margin falling by 2.8 percentage points due to product mix, plant inflationary pressures, and ramp-up costs.
16.5%
West Vantage gross profit margin for the three months ended September 30, 2026
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 3 signals
May 2026 cyber incident caused $7 million revenue impact and production downtime
West Pharmaceutical Services suffered a cybersecurity attack in May 2026 involving data exfiltration and system encryption that caused approximately $7 million in revenue headwind from production downtime.
$7M
revenue growth negatively impacted by production downtime from cyber incident
encryption
West Pharmaceutical records $1.5 million pre-tax restructuring charges in Q2 2026
The company recorded pre-tax charges of $1.5 million in Q2 2026 and $2.9 million for the six months ended June 30, 2026, associated with its January 2025 restructuring plan and 2024 legal structure optimization plan.
$1.5M
pre-tax restructuring charges recorded in Q2 2026
West Vantage gross profit margin drops 3.3 percentage points in Q2 2026
West Vantage gross profit margin decreased by 3.3 percentage points for the three months ended June 30, 2026, due to production downtime from a May 2026 cyber incident and plant spend inflationary pressures.
-3.3%
decrease in West Vantage gross profit margin for Q2 2026
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 1 signal
West Pharmaceutical records $1.4 million in Q1 2026 restructuring and related charges
The company recorded pre-tax charges of $1.4 million in Q1 2026 across existing restructuring initiatives, including depreciation acceleration, lease costs, and legal structure optimization.
$1.4M
pre-tax restructuring charges in Q1 2026
Earnings calls
West Pharmaceutical Services earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 revenue reaches $874M, growing 11.9% organically with 39.7% marginReported net sales grew 8.7% to $874 million, led by Proprietary Products organic growth of 16.6% and over 4 percentage points of price contribution. Gross margin expanded 310 basis points year-over-year to 39.7%, and operating margin reached 25.3% due to mix shift toward high-value products. | |
| Full-year revenue guidance raised to $3.41B-$3.42B rangeFull-year net sales guidance was increased from $3.345B-$3.38B to $3.41B-$3.42B, projecting full-year organic growth of 11.3% to 11.6% compared to the prior 10% to 11%. Adjusted EPS guidance was also raised to $9.38-$9.48, representing 29% to 30% growth year-over-year. | |
| Michel Lagarde assumes President and Chief Executive Officer roleMichel Lagarde recently joined as President and CEO, bringing over a decade of industry executive experience. His initial priorities center on continuous improvement, factory automation, and elevating customer relationships to a strategic level. | |
| Restructuring West Vantage portfolio toward high-value drug handlingThe company is intentionally rolling off lower-margin legacy programs, including a continuous glucose monitoring contract, to pivot West Vantage toward higher-value drug handling. Management expects this transition to exert a muted effect on segment growth through 2027. | |
| Expanding shop floor automation and operational digitization across facilitiesWest is driving plant-level automation and continuous improvement tools to expand capacity, debottleneck sites, and enhance service levels. The initiative was highlighted at the Eschweiler facility in Germany and is being scaled across global functions. | |
| Working capital drag decreases nine-month free cash flow 5%Nine-month free cash flow dropped 5% year-over-year to $278 million due to growth in customer accounts receivable and higher inventory balances required to support ongoing operations. Working capital pressure was partially offset by moderating capital expenditures. |
Signal API · MCP
Track West Pharmaceutical Services with the Signal API
One POST /v1/companies/enrich call with westpharma.com returns West Pharmaceutical Services 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"westpharma.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
Related companies
Questions about West Pharmaceutical Services 10-Q
When did West Pharmaceutical Services file its latest 10-Q?
What did West Pharmaceutical Services disclose in its latest 10-Q?
What did West Pharmaceutical Services say on its recent earnings calls?
Where can I read West Pharmaceutical Services's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .